The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis

Oncotarget
Masataka ShimonosonoShoji Natsugoe

Abstract

Currently, immune checkpoint blockade against members of the B7/CD28 family is being used as a new molecular-targeted therapy, in patients with unresectable advanced or recurrent gastric cancer. Although human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) is a novel molecule of the B7/CD28 family, the clinical impact of its expression remains uncertain in gastric cancer. Consequently, we examined HHLA2 expression in blood specimens from patients with gastric cancer, and investigated the relationship between its expression and clinicopathological factors to assess its potential power as a prognostic blood predictor. Untreated peripheral blood specimens were obtained from 111 patients with gastric cancer and 20 healthy volunteers. HHLA2 mRNA expression levels were determined using quantitative RT-PCR assay. Blood specimens obtained from patients with gastric cancer had significantly lower copies of HHLA2 mRNA than those obtained from healthy volunteers (P < 0.0001). Furthermore, HHLA2 expression was significantly correlated with the depth of tumor invasion (P = 0.0331), distant metastasis (P < 0.0001), and stage of disease (P = 0.0032). The 5-year survival rate was significantly higher in patients wit...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xingxing Zang, James P Allison
May 17, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·UNKNOWN Japanese Gastric Cancer Association
May 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ruihua ZhaoXingxing Zang
Jun 21, 2013·Nature Communications·Yuwen ZhuLieping Chen
Oct 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Dec 19, 2014·Annals of Surgical Oncology·Joshua T ByersYuwen Zhu
Jan 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Murali JanakiramXingxing Zang
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Apr 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yanping Xiao, Gordon J Freeman
Jul 5, 2015·Japanese Journal of Clinical Oncology·Megumi HoriUNKNOWN Japan Cancer Surveillance Research Group
Jul 7, 2017·Molecular Cancer Therapeutics·Ling Ni, Chen Dong
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
PCR

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.